HIGHLIGHTS
- who: Justin A. Chen from the Division of Hematology and Oncology, Davis Comprehensive Center, University of California, X Street, Suite, Sacramento, CA, USA have published the paper: A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer, in the Journal: (JOURNAL)
- what: The aim of this phase I study was to determine the MTD and RP2D of alisertib in combination with gemcitabine.
SUMMARY
In the dose escalation phase, a standard 3 + 3 design was used to determine the maximum tolerated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.